ALK inhibitors(Anaplastic lymphoma kinase inhibitors), EML4-ALK inhibitors(EMAP Like 4-Anaplastic lymphoma kinase fusion inhibitors), MST1R inhibitors(Macrophage-stimulating protein receptor inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [8]

Active Indication

ALK-Positive Inflammatory Myofibroblastic TumorALK-positive anaplastic large cell lymphomaNon-Small Cell Lung Cancer+ [21]

Inactive Indication

Advanced Hepatocellular CarcinomaAdvanced Lung AdenocarcinomaAdvanced Lung Non-Small Cell Carcinoma+ [26]

Originator Organization

Pfizer Global Manufacturing China

Active Organization

Huizhi Pharmaceutical (Dalian) Co., Ltd.Pfizer Europe MA EEIG

IDEAYA Biosciences, Inc.

+ [2]

Inactive Organization-

License Organization

Pfizer Investment Co. Ltd.

China Resources Pharmaceutical Commercial Group Co., Ltd.

Merck & Co., Inc.

+ [2]

Drug Highest PhaseApproved

First Approval Date

United States (26 Aug 2011),

ALK positive Non-Small Cell Lung Cancer

RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Special Review Project (China), Orphan Drug (South Korea), Orphan Drug (Japan)

Structure/Sequence

Molecular FormulaC21H22Cl2FN5O

InChIKeyKTEIFNKAUNYNJU-GFCCVEGCSA-N

CAS Registry877399-52-5

135

Clinical Trials associated with Crizotinib

CTR20252827

/ CompletedNot Applicable

克唑替尼胶囊在健康成年研究参与者中空腹状态及高脂餐后单次口服给药的随机、开放、两周期、两序列、交叉设计生物等效性研究

[Translation] A randomized, open-label, two-period, two-sequence, crossover bioequivalence study of crizotinib capsules in healthy adult study participants after a single oral administration in the fasting state and after a high-fat meal

主要研究目的：研究重庆圣华曦药业股份有限公司生产的克唑替尼胶囊（规格：250mg）在中国健康研究参与者中空腹状态及高脂餐后以口服途径单次给药的药代动力学特征，并以PFIZER EUROPE MA EEIG持有，Pfizer Manufacturing Deutschland mbH,Betriebsstatte Freiburg生产的克唑替尼胶囊（商品名：赛可瑞®/XALKORI®；规格：250mg）为参比制剂，进行生物等效性评价。次要研究目的：初步考察克唑替尼胶囊受试制剂和参比制剂在健康研究参与者中的安全性。

[Translation]

The primary study objective was to investigate the pharmacokinetic characteristics of a single oral dose of crizotinib capsules (250 mg) manufactured by Chongqing Shenghuaxi Pharmaceutical Co., Ltd. in Chinese health study participants, both in the fasting state and after a high-fat meal. Bioequivalence was evaluated using crizotinib capsules (XALKORI®; 250 mg) manufactured by Pfizer Manufacturing Deutschland mbH, Betriebsstatte Freiburg, a subsidiary of PFIZER EUROPE MA EEIG, as the reference formulation. The secondary study objective was to preliminarily investigate the safety of the test and reference formulations of crizotinib capsules in healthy study participants.

Start Date21 Jul 2025

Sponsor / Collaborator

Chongqing Shenghuaxi Pharmaceutical Co. Ltd.

CTR20252385

/ CompletedNot Applicable

克唑替尼胶囊在健康人体随机、开放、两制剂、两周期、交叉、空腹和餐后生物等效性试验

[Translation] A randomized, open-label, two-dose, two-cycle, crossover, fasting and fed bioequivalence study of crizotinib capsules in healthy humans

主要目的：研究健康受试者在空腹/餐后状态下，单次口服北京康立生医药技术开发有限公司的克唑替尼胶囊0.25g（受试制剂）和辉瑞制药（Pfizer Ltd. /PFIZER EUROPE MA EEIG）为持证商的克唑替尼胶囊0.25g（Crizotinib Capsules/XALKORI ® (赛可瑞®)，参比制剂）的相对生物利用度，评价受试制剂和参比制剂的生物等效性。次要目的：通过不良事件发生率、实验室检验结果、生命体征和体格检查等的变化情况观察受试制剂和参比制剂在中国健康受试者中的安全性和耐受性。

[Translation]

Primary objective: To study the relative bioavailability of 0.25g of crizotinib capsules (test preparation) from Beijing Kanglisheng Pharmaceutical Technology Development Co., Ltd. and 0.25g of crizotinib capsules (Crizotinib Capsules/XALKORI ®, reference preparation) from Pfizer Ltd. (PFIZER EUROPE MA EEIG) in healthy subjects in the fasting/postprandial state, and to evaluate the bioequivalence of the test preparation and the reference preparation. Secondary objective: To observe the safety and tolerability of the test preparation and the reference preparation in healthy Chinese subjects through changes in adverse event incidence, laboratory test results, vital signs and physical examinations.

Start Date13 Jul 2025

Sponsor / Collaborator

Beijing Kanglisheng Pharm Tech Development Co. Ltd.

ChiCTR2400092197

/ Not yet recruitingPhase 2IIT

Clinical study of crizotinib in the treatment of amyotrophic lateral sclerosis

Start Date20 Nov 2024

Sponsor / Collaborator

Yichang Central People's Hospital

[+1]

100 Clinical Results associated with Crizotinib

100 Translational Medicine associated with Crizotinib

100 Patents (Medical) associated with Crizotinib

4,599

Literatures (Medical) associated with Crizotinib

01 Dec 2025·MOLECULAR BIOLOGY REPORTS

Advancements in neuroblastoma treatment: FDA-approved drugs and role of phytochemicals

Review

Author: Chandel, Shivani ; Kumar, Rajneesh ; Singh, Rajveer ; Rajpoot, Satyapal

Neuroblastoma (NB) is a solid Pediatric tumor that forms in immature nerve cells. Commonly affecting the adrenal glands, spinal cord, or neck. This cancer is prevalent in children under five years old and accounts for over 15% of cancer-related deaths in this age group. Low-risk tumors can be treated surgically, intermediate-risk tumors require surgery and chemotherapy, and radiation therapy for high-risk Advancements in treatment through FDA-approved drugs and plant-derived compounds. FDA-approved drugs like Entrectinib, Dinutuximab, Unitaxin, Doxorubicin, Hydrochloride, Lorlatinib, and Crizotinib are pivotal in treating neuroblastoma. These agents inhibit pathways such as TrkA/B/C, ROS, and ALK, and the GD2 antigen. In addition to these therapies, phytochemicals have emerged as promising anticancer agents. Compounds such as quercetin, rutin, chalcone, gedunine, lycorine, withaferin A, and resveratrol have anti-cancer properties in preclinical models, targeting tumor growth and apoptosis pathways. These are improving the prevention of tumor growth through cross-reactions. Additional plant extracts have exhibited activity against neuroblastoma. This review highlights the synergistic potential of FDA-approved drugs and plant-derived phytoconstituents in improving neuroblastoma treatment outcomes.

01 Dec 2025·JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Development of a validated and sensitive ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method to simultaneous determination of crizotinib, alectinib and lorlatinib in human plasma

Article

Author: Yang, Meng ; Li, Bo ; Li, Shu ; Chi, Haohua ; Li, Pengmei ; Chen, Wenqian ; Liu, Fang ; Zhang, Cheng ; Zhou, Wei

Crizotinib, alectinib, and lorlatinib are tyrosine kinase inhibitors used sequentially in non-small cell lung cancer (NSCLC) therapy. Therapeutic drug monitoring (TDM) is valuable during sequential treatment, enabling simultaneous quantification. Consequently, an analytical method capable of multiplexing these three compounds into a single assay is highly applicable for routine TDM. A multiplexed UHPLC-MS/MS method quantifying all three drugs was validated for selectivity, matrix effects, linearity (20-1000 ng/mL), accuracy, precision, carryover, and stability. Matrix effects were negligible in both plasma from healthy volunteers and plasma from patients with hyperlipidemia. No significant interfering responses were observed for crizotinib, alectinib, lorlatinib, or their corresponding isotope-labeled internal standards. Sample stability was confirmed under ambient conditions (25 °C) for at least 24 h. Furthermore, the pretreated supernatant remained stable in the auto sampler (15 °C) for 24 h. This validated method is suitable for application in pharmacokinetic studies and exposure-response assessments.

01 Dec 2025·BIOCHEMICAL PHARMACOLOGY

Oncogenic GOPC-ROS1 fusion promotes the formation of lymphatic malformations by impairing tight junction and its crizotinib resistance through repressing ferroptosis

Article

Author: Li, Jing ; Zhan, Zhiyan ; Tian, Ruicheng ; Liang, Huisheng ; Hong, Li ; Gu, Song ; He, Qiao ; Deng, Dan ; Zhang, Rui ; Zhang, Chengchen ; Yin, Xiaowan ; Weng, Zihan

The complicacy of genetic abnormalities in lymphatic malformations (LMs) limits their treatment in clinical practice. In this study, we identified a complex LM with Golgi-associated PDZ and coiled-coil motif containing (GOPC)-proto-oncogene ROS 1 (ROS1) fusion that responds to crizotinib. The oncogenic roles of GOPC-ROS1 fusion in the formation of LMs remain unknown. This study showed that GOPC-ROS1 fusion promotes the proliferation, migration, and invasion of human lymphatic endothelial cells (HLECs). Moreover, fusion of GOPC and ROS1 enhances the catalytic activity of the ROS1 fragment as a receptor tyrosine kinase and alters the profiling of tyrosine phosphorylation in HLECs. Multiple novel tyrosine sites phosphorylated by GOPC-ROS1 in HLECs were validated. Impaired phosphorylation of ZO-1 protein at tyrosine 895, resulting from decreased co-location of GOPC-ROS1 and ZO-1 proteins, inhibits the tight junction of HLECs, which is important for the formation of functional lymphatic vessels. We next investigated the potential mechanisms of crizotinib resistance in GOPC-ROS1⁺ CLM. It was found that high glycolysis and low ferroptosis levels, which are dependent on ENO1-phosY44, contribute to the crizotinib resistance of GOPC-ROS1⁺ HLECs. Targeting ferroptosis by inhibiting System Xc- using sulfasalazine (SASP) represses the crizotinib resistance of GOPC-ROS1⁺ HLECs. A combination of SASP and crizotinib may be a potential therapeutic strategy for various GOPC-ROS1⁺ tumours.

222

News (Medical) associated with Crizotinib

20 Oct 2025

·www.prnewswire.com

IDEAYA Biosciences Reports Positive Median Overall Survival Data from Phase 2 Trial of the Darovasertib and Crizotinib Combination in First-line Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research Congress

Combination demonstrated median overall survival (OS) of 21.1 months, compared to reported historical mOS of approximately 12 months in published meta-analysis of metastatic uveal melanoma in the first-line setting Median progression free survival (PFS) of 7.0 months Confirmed overall response rate (ORR) by RECIST 1.1 of 34%, median duration of response (mDOR) of 9 months and disease control rate (DCR) of 90% SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a leading precision medicine oncology company, announced the first reported median overall survival (OS) results from their Phase 1/2 clinical trial (OptimUM-01) evaluating darovasertib, the company's investigational oral protein kinase C (PKC) inhibitor, in combination with Pfizer's crizotinib1, a c-MET inhibitor, as a first-line treatment for patients with metastatic uveal melanoma (mUM). The data will be presented on Sunday, October 26, 2025 by Dr. Justin Moser at the 2025 Society for Melanoma Research Congress (SMR) taking place in Amsterdam, Netherlands. The presentation at SMR will include data from 44 first-line (1L) mUM patients, including both HLA*A2:01-negative and HLA*A2:01-positive patients, in the single-arm Phase 1/2 OptimUM-01 trial with a median follow-up time of 25 months as of a cut-off date of May 28, 2025. Across all 44 patients treated with the darovasertib and crizotinib combination, a median OS of 21.1 months and a median PFS of 7.0 months was observed. In 41 efficacy-evaluable patients, the confirmed ORR by RECIST 1.1 was 34% (14/41) with a 9.0 month mDOR. A DCR of 90% (37/41) was also observed, with 85% (35/41) of patients achieving 'any reduction' in target lesions. The combination continued to have manageable tolerability, with the most common treatment-related adverse events (TRAEs >30%) of diarrhea, nausea, edema, vomiting, dermatitis, hypoalbuminemia, and fatigue. No Grade 3 or greater TRAEs >5% were observed. The proportion of patients enrolled in the OptimUM-01 study that had baseline ECOG performance status scores (PS) of 0 and 1 was 61% (27/44) and 39% (17/44), respectively. The proportion of patients with ECOG PS 1 in the OptimUM-01 study is approximately two times higher than an earlier published registrational study in mUM. "These first reported overall survival data and broader clinical efficacy observed with a manageable safety profile underscores the potential of the darovasertib and crizotinib combination in the first-line treatment landscape for patients with metastatic uveal melanoma," said Darrin Beaupre, M.D., Ph.D., Chief Medical Officer of IDEAYA Biosciences. "We are encouraged by the clinically meaningful median overall survival, overall response rate, median duration of response, and median progression free survival reported in this first-line metastatic uveal melanoma population and look forward to advancing this combination in the ongoing registrational OptimUM-02 trial," said Meredith McKean, M.D., MPH, Director of Melanoma and Skin Cancer Research for Sarah Cannon Research Institute and principal investigator on the trial. Metastatic uveal melanoma is a rare and aggressive form of ocular cancer with poor prognosis, where historical median OS reported in published meta-analysis from patients in the treatment naïve setting is approximately 12 months (ES Rantala et al, Melanoma Research, 2019; L Khoja et al, Annals of Oncology, 2019). IDEAYA is conducting a registration-enabling Phase 2/3 trial (OptimUM-02) of the darovasertib and crizotinib combination in 1L HLA*A2:01-negative mUM and is targeting to report median PFS data from this trial by year-end 2025 to Q1 2026 to support a potential U.S. accelerated approval filing. A presentation summary of the SMR data will be available on the Investor Relations tab of IDEAYA's corporate website after the presentation. About IDEAYA Biosciences IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer. Forward-Looking Statements This press release contains forward-looking statements, including, but not limited to, statements related to (i) the potential therapeutic benefits of darovasertib, including in combination with crizotinib; (ii) the safety profile of darovasertib; (iii) the timing of reporting median PFS data from Phase 2/3 OptimUM-02 trial; and (iv) the potential for accelerated approval in 1L HLA*A2 negative mUM. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA's preclinical and clinical development programs, commercialization of products, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA's programs' in early or late stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with the manufacturing or commercialization of drug products, the outcome of pricing, coverage and reimbursement negotiations with third-party payors for IDEAYA's products, IDEAYA's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. Neither Breakthrough Therapy nor Orphan Drug designations, nor any clinical study results, whether preliminary or final, necessarily translate into a successful outcome in another study or approval of the drug. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's Annual Report on Form 10-K dated February 18, 2025, and any current and periodic reports filed with the U.S. Securities and Exchange Commission. Investor and Media Contact IDEAYA Biosciences Joshua Bleharski, Ph.D. Chief Financial Officer [email protected] SOURCE IDEAYA Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical ResultPhase 2

20 Oct 2025

·endpoints.news

Ideaya’s drug saves almost 60% of eye cancer patients from surgery in Phase 2 trial

BERLIN – Ideaya Biosciences said its protein kinase C inhibitor delivered positive mid-stage results in a subset of eye cancer patients, bolstering expectations for one of the cohorts in an ongoing registrational study. After treatment with the biotech’s drug, called darovasertib, 59% of patients with primary uveal melanoma (UM) who were candidates for eye removal surgery were able to opt for radiation therapy instead. The data were presented Monday at the European Society for Medical Oncology’s annual congress in Berlin. “With more than half of the safety and efficacy data now publicly available [for darovasertib], we don’t expect any surprises on the final readout” for the mid-stage trial, Mizuho Securities analysts wrote in response to the release of the ESMO abstract last week. Those final data are expected in the first half of 2026. The 120-patient Phase 2 study also enrolled a separate cohort of primary UM patients who are candidates for a type of radiation therapy called plaque brachytherapy (PB). Last month, Ideaya said almost half of those patients reduced their dose of radiation to key parts of the eye by at least 20%. The company believes that reducing radiation can help preserve long-term vision. The biotech is also running a Phase 3 trial called OptimUM-10, which is enrolling 520 primary UM patients requiring either eye removal surgery or PB. The primary endpoint for the surgery cohort is tracking how many patients can save their affected eye, while the PB cohort’s primary endpoint is the proportion of patients with a certain level of vision preservation. The Phase 2 surgery cohort data are “encouraging” for the Phase 3 trial, Leerink analysts wrote last week in response to the ESMO abstract. But they said it’s less certain whether radiation dose reduction alone will translate to vision preservation in the Phase 3 PB patients. That could also depend on factors such as “location of the radiation and degree of edema,” they explained. Last month, Ideaya said that 13 patients in the Phase 2 PB cohort reported improvements in their vision during the neoadjuvant treatment period, gaining an average of six letters in a visual acuity test. Goldman Sachs analysts have said that darovasertib could hit $3 billion in peak sales. The drug is also being investigated in combination with Pfizer’s Xalkori in a Phase 2/3 study focused on patients with metastatic melanoma who have tested negative for the HLA-A2 antigen. The presentation at ESMO also featured detailed safety results. The most common side effects associated with darovasertib in the Phase 2 trial were diarrhea (48%), nausea (43%) and fatigue (30%). The only grade 3 or higher event that occurred in more than 5% of patients was low blood pressure.

Clinical ResultPhase 2Radiation TherapyPhase 3

20 Oct 2025

·firstwordpharma.com

ESMO25: IDEAYA's darovasertib impresses in twin ocular cancer trials

IDEAYA Biosciences' experimental eye cancer drug darovasertib is showing signs it could both reduce tumour volume in uveal melanoma and preserve vision, a dual win that sent company shares up nearly 5% Monday.At the European Society for Medical Oncology (ESMO) conference, it reported results from the Phase II OptimUM-09 trial, which tested darovasertib, an oral protein kinase C inhibitor, as neoadjuvant therapy in patients with primary uveal melanoma. As of the June 13 data cut-off, 94 patients were evaluable for efficacy, including patients recommended for enucleation and those eligible for plaque brachytherapy.Ocular tumours shrank in 83% of patients, with over half (54%) seeing reductions of 20% or more. Among those initially slated for eye removal, 57% (24/42) ultimately preserved their eye, a rate that climbed to 95% (19/20) for patients who saw ≥20% tumour shrinkage.The results surpassed expectations. "For enucleation, we projected that a ≥22% eye preservation rate (assuming 50 evaluable patients) would clear" the Phase III bar, noted Silvan Türkcan, an analyst at Citizens JMP. But at 57%, IDEAYA's readout revealed an eye preservation rate "well above the FDA threshold and included that 55% of individuals had improved visual acuity scores compared to baseline," Türkcan added.Following discussions with the FDA, the company is proposing to define response as ≥20% tumour shrinkage in its ongoing Phase III OptimUM-10 trial of darovasertib in the neoadjuvant setting for primary uveal melanoma.Darovasertib was well tolerated, with "manageable" side effects such as diarrhoea, nausea, vomiting and fatigue. The company said serious treatment-related events were uncommon (5.3%), with 6.3% of patients discontinuing therapy due to adverse effects.Combo with XalkoriMeanwhile, IDEAYA also shared results from another trial – OptimUM-01 – to be presented at the Society for Melanoma Research (SMR) meeting taking place later in a week. The single-arm Phase I/II study is evaluating a combination of darovasertib plus Pfizer's Xalkori (crizotinib) in first-line metastatic uveal melanoma.IDEAYA will present data from 44 first-line participants, including both HLA*A2:01–positive and –negative patients, with a median follow-up of 25 months as of the May 28 cutoff. According to the company, the combination yielded median overall survival of 21.1 months – well above the roughly 12-month historical benchmark – and median progression-free survival (PFS) of 7 months.The confirmed overall response rate (ORR) was 34%, median duration of response was 9 months and disease control rate was 90%.IDEAYA is conducting the registration-enabling Phase II/III OptimUM-02 trial of the combination in first-line HLA*A2:01-negative metastatic patients, targeting median PFS data by year-end 2025 to first quarter 2026 to support a potential US accelerated approval filing."We'll reserve a definitive judgment until the complete results are available, but the results outlined in the abstract give us reason for optimism," Citizen JMP's Türkcan said. In September, France's Servier licensed ex-US rights to darovasertib in a deal valued at up to $530 million.

Clinical ResultPhase 3AcquisitionAccelerated ApprovalPhase 2

100 Deals associated with Crizotinib

External Link

KEGG	Wiki	ATC	Drug Bank
D09731	Crizotinib	L01XE16	DB08865

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
ALK-Positive Inflammatory Myofibroblastic Tumor	United States	PF Prism CV	14 Jul 2022
ALK-positive anaplastic large cell lymphoma	United States	PF Prism CV	14 Jan 2021
Non-Small Cell Lung Cancer	China	Pfizer Inc.	22 Jan 2013
Reactive oxygen species 1 positive non-small cell lung cancer	South Korea	Pfizer Inc.	29 Dec 2011
ALK positive Non-Small Cell Lung Cancer	United States	PF Prism CV	26 Aug 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Uveal Melanoma	Phase 3	United States	IDEAYA Biosciences, Inc.	31 Oct 2023
Uveal Melanoma	Phase 3	Australia	IDEAYA Biosciences, Inc.	31 Oct 2023
Uveal Melanoma	Phase 3	Belgium	IDEAYA Biosciences, Inc.	31 Oct 2023
Uveal Melanoma	Phase 3	Canada	IDEAYA Biosciences, Inc.	31 Oct 2023
Uveal Melanoma	Phase 3	France	IDEAYA Biosciences, Inc.	31 Oct 2023
Uveal Melanoma	Phase 3	Germany	IDEAYA Biosciences, Inc.	31 Oct 2023
Uveal Melanoma	Phase 3	Israel	IDEAYA Biosciences, Inc.	31 Oct 2023
Uveal Melanoma	Phase 3	Italy	IDEAYA Biosciences, Inc.	31 Oct 2023
Uveal Melanoma	Phase 3	Netherlands	IDEAYA Biosciences, Inc.	31 Oct 2023
Uveal Melanoma	Phase 3	Poland	IDEAYA Biosciences, Inc.	31 Oct 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESMO_ELCC2025	Not Applicable	ROS1 fusion positive Neoplasms G2032R mutation \| secondary ROS1 mutation (G2032R, D2033N, L2026M, S1986F)	140	Next-generation ROS1-TKI (repotrectinib, taletrectinib, TL-139)	zthkipyeuk(rthtpoiyfo) = bznqlistyg kjttdtptrh (lpiltbjweq ) View more	-	26 Mar 2025
				Non-next-generation TKI	zthkipyeuk(rthtpoiyfo) = ykqgvqpeoq kjttdtptrh (lpiltbjweq ) View more
ESMO_ELCC2025	Not Applicable	ROS1 fusion positive Neoplasms	78	Crizotinib	gsxlvueesr(domgzjcqld) = psjkddshvv dgtvzetlma (sifvfmeaoo ) View more	Positive	26 Mar 2025
				crizotinib (Brain-RT)	gsxlvueesr(domgzjcqld) = tguzonvtku dgtvzetlma (sifvfmeaoo )
NCT01121588 (PROFILE 1013 \| A8081013, CTgov)	Phase 1	ALK Positive Solid Tumors	44	crizotinib (ALCL Arm)	ysngpwnbyp = djykohiojg wpxdfyjqjw (iydykcduze, tmrrszaxts - zvthcrxqhq) View more	-	23 Jan 2025
				crizotinib (IMT Arm)	ysngpwnbyp = lvhkziajad wpxdfyjqjw (iydykcduze, fawysbwdix - lpqnpxmumb) View more
NCT02737501 (ALTA-1L, Pubmed \| BMC Med Res Methodol)	Phase 3	-	-	Brigatinib	ndowqvdgqs(jpwioslmws): P-Value = 0.50	Positive	20 Dec 2024
				Crizotinib
NCT01979536 (ANHL12P1, ASH2024)	Phase 2	ALK-positive anaplastic large cell lymphoma NPM::ALKfusion transcript \| Ab to ALK	137	Brentuximab Vedotin	mbayzdxzif(svfphfpszu) = qakssltcgb hisvgfepgo (negukexyvr ) View more	Positive	07 Dec 2024
				Crizotinib	mbayzdxzif(svfphfpszu) = wdcvpeqjsk hisvgfepgo (negukexyvr ) View more
NCT00828919 (CTgov)	Not Applicable	Solid tumor	52	Axitinib (Overall)	blwqenbbzi = njqmqjbhgh niegzxypqs (fvhcjhjkxq, yznpxwcosx - dwkofxdvdg) View more	-	03 Dec 2024
				Axitinib (Axitinib 2 mg)	blwqenbbzi = atkwrpsxba niegzxypqs (fvhcjhjkxq, kzqircbgth - bdkcdcjuaq) View more
Literature Manual	Not Applicable	Advanced Lung Adenocarcinoma EML4-ALK Fusion \| MET Amplification	1	克唑替尼+洛拉替尼	yirfdqomsj(ijrlbzukbt) = 该患者克唑替尼与洛拉替尼联合治疗16 d，克唑替尼治疗洛拉替尼耐药后的无进展生存期）为47 d。 dsxhhwkhdi (zmadrunsyo )	Positive	01 Dec 2024
NCT03672643 (CTgov)	Phase 4	Advanced Lung Non-Small Cell Carcinoma	41	Crizotinib	buvujcxyjs = shljkffmxy aipchuvdgw (ykhkdryxma, qbdtzbxhrt - blxltdwxnm) View more	-	08 Nov 2024
NCT04084717 (ESMO2024) Manual	Phase 2	c-Met positive non-small cell lung cancer First line MET Amplification \| MET Exon 14 Skipping	28	Crizotinib 250 mg BID	nreeyvlnxo(sokllksycn) = wbfreqsecs qyxqqffjfc (wprvkzxehg ) View more	Positive	14 Sep 2024
				Crizotinib 250 mg BID (MET amp)	nreeyvlnxo(sokllksycn) = trqtnmkkkz qyxqqffjfc (wprvkzxehg )
WCLC2024 Manual	Not Applicable	Non-Small Cell Lung Cancer Second line ALK Positive \| MET Amplification	1	Alectinib and CrizotinibBrigatinib	hepevricjr(njjmsoyygq) = izqsvwiamx lfjwjivquf (oyqlgfvrzr )	Positive	07 Sep 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis